Gibbspowell1989

Adjacent segment disease occurred in three dogs (30%) with DACSM at a mean of 11 months postsurgery. CONCLUSION The use of the C-LOX implant for dogs with cervical spondylomyelopathy resulted in a high rate of initial neurological improvement; however, there is a moderate incidence of minor and major complications that is comparable to previously described distraction-stabilisation techniques. © 2020 Australian Veterinary Association.OBJECTIVE As ownership of brachycephalic dog breeds rises, the surgical correction of components of brachycephalic airway syndrome (BAS) is increasingly recommended by veterinarians. This study's objective was to describe the incidence of, and strategies for the management of post-operative respiratory complications in brachycephalic dogs undergoing surgical correction of one or more components of BAS. METHODS Medical records of 248 brachycephalic dogs treated surgically for BAS were retrospectively reviewed for demographic information, procedures performed, post-operative complications and treatment implemented, hospitalisation time, and necessity for further surgery. RESULTS Pugs, Cavalier King Charles Spaniels and British Bulldogs were the most commonly encountered breeds. Dogs which experienced a complication were significantly older (mean was 5.5 years, compared with 4.1 years [P less then 0.01]). Fifty-eight dogs (23.4%) had complications which included dyspnoea managed with supplemental oxygen alone (7.3%, n = 18), dyspnoea requiring anaesthesia and re-intubation (8.9%, n = 22), dyspnoea necessitating treatment with a temporary tracheostomy (8.9%, n = 22), aspiration pneumonia (4%, n = 10), and respiratory or cardiac arrest (2.4%, n = 6). Five of the 22 dogs requiring anaesthesia and re-intubation deteriorated 12 or more hours after post-surgical anaesthetic recovery. The overall mortality rate in this study was 2.4% (n = 6). Age, concurrent airway pathology, and emergency presentation significantly predicted post-operative complications. CONCLUSION Our data show the importance of close monitoring for a minimum of 24 h following surgery by an experienced veterinarian or veterinary technician. Surgical intervention for BAS symptomatic dogs should be considered at an earlier age as an elective procedure, to reduce the risk of post-operative complications. A-769662 datasheet © 2020 Australian Veterinary Association.The occurrence of mutations in the BCR-ABL1 kinase domain (KD) can lead to treatment resistance in chronic myeloid leukaemia patients. Nowadays, next-generation sequencing (NGS) is an alternative method for the detection of kinase domain mutations, compared to routinely used Sanger sequencing, providing a higher sensitivity of mutation detection. However, in the protocols established so far multiple rounds of amplification limit reliable mutation detection to approximately 5% variant allele frequency. Here, we present a simplified, one-round amplification NGS protocol for the Illumina platform, which offers a robust early detection of BCR-ABL1 KD mutations with a reliable detection limit of 3% variant allele frequency. © 2020 British Society for Haematology and John Wiley & Sons Ltd.Systemic immunosuppressive treatments (IS) are restricted to severe atopic dermatitis (AD) in children. We described the IS use (first and second-line) for children with AD in a French retrospective national cohort, by using two survival analyses 'drug survival' (DS, defined as the duration of treatment) and 'post-drug survival' (PDS, defined as the time between the end of first-line and the beginning of second-line). This article is protected by copyright. All rights reserved.BACKGROUND We previously found that serum levels of C-X-C motif chemokine 10 (CXCL10) decreased after PsA onset. OBJECTIVE We measured CXCL10 levels over time in psoriasis patients who developed PsA to determine whether the drop in CXCL10 was specific to these patients and further assess its association with PsA development. METHODS Prospectively followed psoriasis patients without arthritis (psoriasis cutaneous [PsC]) were assessed yearly by rheumatologists for the presence of PsA. PsC patients who developed PsA (converters) were matched to those that did not develop PsA (non-converters) based on psoriasis duration and the interval between follow-up visits. The duration between baseline and the first visit post-conversion in converters was used to assign a pseudo-conversion date in non-converters. Linear mixed-effects models were used to model the expression of CXCL10 over time. RESULTS CXCL10 significantly declined over time in converters prior to PsA development with a significant difference in the trend over time between converters (n=29) and non-converters (n=52; p less then 0.001). CXCL10 continued to decline after PsA onset in a subset of converters. There was a significant difference in the trend of CXCL10 levels between converters (n=24) and non-converters (n=16; p=0.01) pre-conversion/pseudo-conversion. This difference remained post-conversion (p=0.006) and was not different from the pre-conversion period (p=0.75). CONCLUSION A large difference in CXCL10 was identified in PsC patients that are destined to develop PsA over time. This exploratory analysis supports the association of CXCL10 with PsA development in PsC patients and warrants further study of the predictive ability of this chemokine. This article is protected by copyright. All rights reserved.BACKGROUND AND PURPOSE Nonalcoholic fatty liver disease (NAFLD) is a worldwide public health concern with no established pharmacological therapy. Here, we explored the potential pharmacological action of P7C3-A20, a novel aminopropyl carbazole compound with neuroprotective activity, in a high-fat diet (HFD)-induced mouse NAFLD model. EXPERIMENTAL APPROACH Mice were fed with HFD (42% fat for energy) for 16 weeks to induce NAFLD. P7C3-A20 (20 mg/kg/d) was administrated orally for 2 weeks. Indirect calorimetry, histology analysis, immunoblotting, immunohistochemistry, and biomedical examinations were performed. Gut microbiota were determined using a 16s ribosomal RNA sequencing analysis. KEY RESULTS P7C3-A20 treatment reduced body weight gain/adiposity, improved insulin resistance, promoted energy expenditure (O2 consumption/CO2 production), inhibited lipid oxidation, suppressed hepatic inflammation (Kupffer cell number and pro-inflammatory factors), decreased necroptosis/apoptosis (receptor-interacting serine-threonine kinase 3 [Ripk3], cleaved caspase-3 and TUNEL), and alleviated liver fibrosis and injury.